<DOC>
	<DOCNO>NCT02609984</DOCNO>
	<brief_summary>This open-label Phase 2 randomize study examine use study agent , CMB305 ( sequentially administer LV305 [ dendritic cell-targeting viral vector express NY-ESO-1 gene ] G305 [ NY-ESO-1 recombinant protein plus GLA-SE ] ) combination atezolizumab atezolizumab alone , patient locally advance , relapse metastatic sarcoma ( synovial myxoid/round cell liposarcoma ) express NY-ESO-1 protein . CMB305 novel approach design stimulate body 's immune system fight spread growth cancer patient whose tumor express NY-ESO-1 protein . LV305 give prime-boost approach G305 induce potentially synergistic immunotherapeutic response combination atezolizumab .</brief_summary>
	<brief_title>Trial CMB305 Atezolizumab Patients With Sarcoma</brief_title>
	<detailed_description>This study design investigate examine time progression CMB305 combination atezolizumab atezolizumab alone treatment patient sarcoma express NY-ESO-1 protein .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Selected Locally advanced , relapse , metastatic sarcoma measurable tumor burden follow therapy , define RECIST v1.1 ; total lesion must ≤12 cm ( synovial sarcoma ) ≤15 cm ( myxoid/round cell liposarcoma [ MRCL ] ) . Tumor histology consistent synovial sarcoma MRCL . Tumor specimen positive NYESO1 expression IHC . Inadequate response , relapse , and/or unacceptable toxicity ≥ 1 prior systemic , surgical , radiation cancer therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Selected Investigational therapy within 4 week prior CMB305 dose Prior administration NYESO1targeting immunotherapeutics . Prior treatment CD137 agonists immune checkpoint blockade therapy , include antiCTLA4 , anti PD1 , anti PDL1 therapeutic antibody , antibody drug target Tcell costimulation . Treatment systemic immunostimulatory agent ( include limit interleukin2 ) within 4 week five halflives drug , whichever short , prior first dose . Significant immunosuppression . Other cancer therapy , include chemotherapy , radiation , biologics kinase inhibitor within 3 week prior first schedule dosing . History autoimmune disease , include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia ) , risk pulmonary toxicity , evidence active pneumonitis screen chest CT scan . History radiation pneumonitis radiation field ( fibrosis ) permit . History cancer within 3 year . Evidence active tuberculosis recent ( &lt; 1 week prior first schedule dosing ) clinically significant infection require systemic therapy . Evidence active hepatitis B ( HepB ) , hepatitis C ( HepC ) , Human Immunodeficiency Virus ( HIV ) infection . Known active untreated central nervous system ( CNS ) metastases . Pregnant , plan become pregnant within 6 month treatment , nursing . Known allergy ( y ) component CMB305 , atezolizumab , severe allergic reaction monoclonal antibody , fusion protein , CHO cell product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>CMB305</keyword>
	<keyword>LV305</keyword>
	<keyword>GLA-SE</keyword>
	<keyword>Atezolizumab</keyword>
	<keyword>NY-ESO-1</keyword>
</DOC>